| Trial ID: | L3625 |
| Source ID: | NCT00064714
|
| Associated Drug: |
Ac2993 (Exenatide)
|
| Title: |
Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: AC2993 (exenatide)|DRUG: daclizumab (immunosuppressive)
|
| Outcome Measures: |
Primary: Change in basal C-peptide level, Assess whether patients treated with AC2993 (with or without concomitant immunosuppression) will display at least a 50% improvement in their basal C-peptide level. C-peptide level is a surrogate measure for insulin production., baseline and 6 months |
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
47
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-07
|
| Completion Date: |
2008-03
|
| Results First Posted: |
|
| Last Update Posted: |
2015-03-11
|
| Locations: |
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00064714
|
